Johnson Investment Counsel Inc. Sells 5,430 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Johnson Investment Counsel Inc. lowered its position in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 6.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 84,571 shares of the company’s stock after selling 5,430 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Option Care Health were worth $1,962,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of OPCH. Wealth Enhancement Advisory Services LLC bought a new position in shares of Option Care Health during the 3rd quarter worth approximately $206,000. Atria Investments Inc bought a new position in shares of Option Care Health during the 3rd quarter worth approximately $213,000. Victory Capital Management Inc. raised its holdings in shares of Option Care Health by 4,432.8% in the 3rd quarter. Victory Capital Management Inc. now owns 1,621,593 shares of the company’s stock worth $50,756,000 after purchasing an additional 1,585,818 shares during the period. Geneva Capital Management LLC bought a new stake in shares of Option Care Health in the 3rd quarter worth approximately $24,679,000. Finally, KBC Group NV raised its holdings in shares of Option Care Health by 16.2% in the 3rd quarter. KBC Group NV now owns 5,013 shares of the company’s stock worth $157,000 after purchasing an additional 700 shares during the period. Institutional investors own 98.05% of the company’s stock.

Analyst Upgrades and Downgrades

OPCH has been the topic of a number of research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a report on Friday, January 10th. UBS Group initiated coverage on shares of Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target on the stock. Barrington Research lifted their price target on shares of Option Care Health from $33.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, February 27th. JPMorgan Chase & Co. lifted their price target on shares of Option Care Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Finally, Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $26.00 to $33.00 in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Option Care Health Stock Up 0.1 %

Option Care Health stock opened at $33.42 on Wednesday. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $34.85. The firm has a market capitalization of $5.52 billion, a price-to-earnings ratio of 28.08, a P/E/G ratio of 2.30 and a beta of 1.33. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The firm has a 50 day simple moving average of $30.25 and a 200 day simple moving average of $28.19.

Insider Activity at Option Care Health

In other news, insider Michael Bavaro sold 30,996 shares of the business’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the completion of the transaction, the insider now directly owns 44,974 shares in the company, valued at $1,495,835.24. The trade was a 40.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.64% of the stock is owned by company insiders.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.